Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

SBL Vaccin AB manufactures and distributes vaccines. Its products are used for the treatment of polio, diarrhoea, and cholera diseases. The company distributes products to the healthcare centers, hospitals, schools, and industrial healthcare units. SBL Vaccin was founded in 1957 and is located in Solna, Sweden.

The University of Iowa Research Foundation (UIRF) - a 501C3 corporation - commercializes University of Iowa developed technologies and inventions through licensing and new venture formation, and manages the subsequent revenue stream.

Shanghai Junshi Biosciences Co., Ltd. engages in the discovery, development, clinical research, and commercialization of biopharmaceutical drugs. Its products include toripalimab injection, UBP1211, JS002, and UBP1213. The company was founded by Zhuo Bing Zhang and Ji Kuan Shan on December 27, 2012 and is headquartered in Shanghai, China.

RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.

OSSIANIX is a privately held biotherapeutics company that develops single domain antibodies based on the highly versatile VNAR structure from shark. Due to remarkable biological and biophysical properties, the VNAR platform can rapidly deliver unique, exquisitely high-affinity products to multiple target classes and overcomes most disadvantages of conventional monoclonal antibody therapy. The platform is also ideal for generating bispecific and trispecific products that can be engineered with ease to develop products with differentiated features in clinically meaningful conditions and also allow targeting to both the blood brain barrier and GI tract for CNS and oral applications.

Autobio Diagnostics is a company mainly engaged in development, manufacture and sales of diagnostics products.

Yakult Honsha Co., Ltd. engages in the manufacture and sale of food and beverage products, cosmetics, and pharmaceuticals. It operates through the following segments: Food and Beverages in Japan, the Americas, Asia and Oceania, and Europe; Pharmaceuticals, and Others. The Food and Beverages segment produces and merchandises milk drinks, noodles, juices, and soft drinks. The Pharmaceuticals segment manufactures and sells anti-cancer drugs and other pharmaceutical products. The Others segment includes cosmetics and professional baseball team management. The company was founded by Minoru Shirota in 1935 and is headquartered in Tokyo, Japan.

ACROBiosystems Co., Ltd. engages in the development of biomedicine and bio-protein technology. Its products include fluorescent label protein, immune-checkpoint protein, and cytokine. The company was founded on July 22, 2010 and is headquartered in Beijing, China.

Shanghai New World Genetic Technology Development Co., Ltd., established on 2001-06-12, The scope of business includes technology development and research in the fields of biotechnology and medicine,technology transfer,technical consulting,Technical Services,Investment consulting in fields related to biotechnology and medicine,Management Consulting(Operating with a license involving licensed operations).

Wuhan Jiyuan High-tech Co., Ltd., established on 2013-05-30, Business scope includes stem cells,R&D of immune cells,technical consulting,technology transfer,storage service;Biotechnology,medical instruments,Biological Beauty and Health Products,Research and development of biological cell anti-aging technology,technical consulting,technology transfer;Sales of Class I Medical Devices.(Projects subject to approval by law,Business activities can only be carried out after approval by relevant departments)

ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.

Jiangsu Simcere Pharmaceutical Co., Ltd., a subsidiary of Jiangsu Simcere Medical Diagnostics Co., Ltd., is a Chinese company located in Nanjing. The firm manufactures and sells pharmaceutical products. It was founded in 1995.

Jiangsu Xiansheng Pharmaceutical Research Co., Ltd., established on 2004-02-10, Business scope includes licensed business items:No general operating items:medical products,Research on medical diagnostic reagents,Technology transfer and related technical consulting services.Self-operated and agent import and export business of various commodities and technologies.*

Forevernk, Inc., part of H&B Design Co., Ltd., is a South Korean company located in Seoul. The firm provides healthcare solutions. It was acquired by H&B Design Co., Ltd. on September 13, 2021.

Part of AstraZeneca PLC, Cambridge Antibody Technology Group Ltd. is a British company located in Cambridge that functions as an holding company whose subsidiaries researches, develops and exploits molecular engineering products. It was founded in 1996.

Dyax Corp. (Dyax) is a biopharmaceutical company focused on the discovery, development and commercialization of biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company's lead product, DX-88, has been approved under the brand name KALBITOR (ecallantide) by the United States Food and Drug Administration (FDA) for treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. The Company commercializes KALBITOR on its own in the United States. In addition to its approved commercial use for HAE in the United States, the Company is also developing DX-88 through collaborations in other indications. These include use of DX-88 for the reduction of blood loss during surgery in collaboration with Cubist Pharmaceuticals (Cubist), and for treatment of retinal diseases in collaboration with Fovea Pharmaceuticals (Fovea), which was acquired by sanofi-aventis during the year ended December 31, 2009.

Vitorgan Arzneimittel GmbH is a German private company located in Ostfildern that produces bio molecular homeopathic medicines. It was founded in 1954 by Irene Regena Theurer and Karl Eugen Theurer. Stefan Back and Karl Georg Theurer are the current co-CEOs of the firm.